Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 487241, 2 pages
http://dx.doi.org/10.1155/2015/487241
Editorial

Neuroinflammation and Neurodegeneration: Pinpointing Pathological and Pharmacological Targets

1Department of Pharmacology, Federal University of State Minas Gerais, Avenida Antonio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil
2Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA
3Department of Psychiatry, University of Freiburg Medical School, Hauptstrasse 5, 79104 Freiburg, Germany
4Department of Psychiatry, University of California San Francisco, School of Medicine, San Francisco, CA 94143-0984, USA
5Asklepios-Med, Kossuth Lajos Sugárút 23, 6722 Szeged, Hungary

Received 20 June 2015; Accepted 24 June 2015

Copyright © 2015 Antonio Carlos Pinheiro de Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


For many years, the brain had been regarded as an immune-privileged organ because of an old tenet which stated that no classical immune activation or inflammation could take place intrathecally. However, this theory has quickly changed with the advent of several studies demonstrating that the central nervous system (CNS) is in fact immunologically specialized [1, 2].

Neuroinflammation has been viewed as a double-edged sword: it not only is essential for the recovery from a number of conditions, but also may play detrimental roles in neurodegenerative processes. In such disorders inflammation can be set off by versatile triggers: protein aggregates, mediators released from injured neurons, accumulation of abnormally modified cellular components, and suppression of mechanisms that would normally control inflammatory processes, just to mention a few [3].

Given the increased life-expectancy, the incidence of neurodegenerative diseases is steadily rising. In light of this, research into this large segment of neuropsychiatry is a top priority around the globe, and one of the main areas of focus is to understand neuroinflammation that underlies, at least in part, the most common degenerative conditions of the brain: Alzheimer’s dementia, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s chorea, and many others [46]. By addressing intrathecal inflammation, some of these disorders could be prevented or even successfully treated.

This special issue compiles original articles and reviews dissecting various pharmacological targets of inflammation that may serve as a springboard for opening innovative therapeutic avenues and could be germane to advanced research in neurodegenerative disorders.

Antonio Carlos Pinheiro de Oliveira
Eduardo Candelario-Jalil
Bernd L. Fiebich
Magda da Silva Santos
András Palotás
Helton José dos Reis

References

  1. H.-M. Gao and J.-S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-M. Lucas, N. J. Rothwell, and R. M. Gibson, “The role of inflammation in CNS injury and disease,” British Journal of Pharmacology, vol. 147, no. 1, pp. S232–S240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Wyss-Coray and L. Mucke, “Inflammation in neurodegenerative disease—a double-edged sword,” Neuron, vol. 35, no. 3, pp. 419–432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. M. Craft, D. M. Watterson, and L. J. Van Eldik, “Neuroinflammation: a potential therapeutic target,” Expert Opinion on Therapeutic Targets, vol. 9, no. 5, pp. 887–900, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. M. Hoozemans, R. Veerhuis, J. M. Rozemuller, and P. Eikelenboom, “Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology,” International Journal of Developmental Neuroscience, vol. 24, no. 2-3, pp. 157–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Minghetti, “Role of inflammation in neurodegenerative diseases,” Current Opinion in Neurology, vol. 18, no. 3, pp. 315–321, 2005. View at Publisher · View at Google Scholar · View at Scopus